Published in Cell Transplant on November 05, 2010
The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol (2011) 1.16
Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease-A Phase II Study. Stem Cells Int (2011) 0.97
Enhanced mesenchymal stromal cell recruitment via natural killer cells by incorporation of inflammatory signals in biomaterials. J R Soc Interface (2011) 0.95
IFN-γ stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro. Stem Cells Dev (2013) 0.92
Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors. Mediators Inflamm (2013) 0.91
Stem cells isolated from the human stromal limbus possess immunosuppressant properties. Mol Vis (2012) 0.88
The regulation of inflammatory mediators in acute kidney injury via exogenous mesenchymal stem cells. Mediators Inflamm (2014) 0.82
Liver myofibroblasts from hepatitis B related liver failure patients may regulate natural killer cell function via PGE2. J Transl Med (2014) 0.78
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality? Int J Mol Sci (2016) 0.76
Stem cell mechanisms during left ventricular remodeling post-myocardial infarction: Repair and regeneration. World J Cardiol (2014) 0.76
Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy. World J Stem Cells (2017) 0.75
Selective expansion of human natural killer cells leads to enhanced alloreactivity. Cell Mol Immunol (2013) 0.75
Activated Tissue-Resident Mesenchymal Stromal Cells Regulate Natural Killer Cell Immune and Tissue-Regenerative Function. Stem Cell Reports (2017) 0.75
Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med (2002) 5.34
Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica (2007) 3.03
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood (2014) 2.72
EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res (2008) 2.39
Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2006) 2.29
Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica (2008) 2.20
Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer (2009) 2.12
Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood (2007) 2.09
Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica (2008) 1.80
Current trends in hematopoietic stem cell transplantation in Europe. Blood (2002) 1.72
Impact of HLA-DPB1 haplotypes on outcome of 10/10 matched unrelated hematopoietic stem cell donor transplants depends on MHC-linked microsatellite polymorphisms. Biol Blood Marrow Transplant (2011) 1.63
Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease. Am J Respir Crit Care Med (2014) 1.58
Association of TNFd and IL-10 polymorphisms with mortality in unrelated hematopoietic stem cell transplantation. Transplantation (2006) 1.49
Low risk of anti-human leukocyte antigen antibody sensitization after combined kidney and islet transplantation. Transplantation (2008) 1.47
Significant progress in palliative treatment of non-small cell lung cancer in the past decade. Chest (2005) 1.43
Initial cord blood unit volume affects mononuclear cell and CD34+ cell-processing efficiency in a non-linear fashion. Cytotherapy (2011) 1.43
Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol (2008) 1.42
Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol (2011) 1.38
IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One (2008) 1.38
Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica (2013) 1.36
BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol (2004) 1.29
IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. Eur J Immunol (2010) 1.20
Economics, health care systems and utilization of haematopoietic stem cell transplants in Europe. Br J Haematol (2002) 1.19
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood (2005) 1.18
Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation. Biol Blood Marrow Transplant (2010) 1.15
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol (2004) 1.15
The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res Ther (2007) 1.13
Non-hematopoietic human bone marrow contains long-lasting, pluripotential mesenchymal stem cells. J Cell Physiol (2004) 1.13
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood (2013) 1.11
Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance. Antimicrob Agents Chemother (2006) 1.11
Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica (2010) 1.09
Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosuppression. Ann Intern Med (2002) 1.08
Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp Hematol (2007) 1.07
Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia. Ann Hematol (2004) 1.07
Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. Int J Radiat Oncol Biol Phys (2007) 1.06
B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport (2005) 1.05
Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int (2007) 1.04
Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol (2009) 1.03
Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae. Antimicrob Agents Chemother (2005) 1.02
Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transplantation in Fanconi anemia patients. Haematologica (2010) 1.02
Impact of selection of cord blood units from the United States and swiss registries on the cost of banking operations. Transfus Med Hemother (2013) 1.02
Haplotype-based banking of human pluripotent stem cells for transplantation: potential and limitations. Stem Cells Dev (2012) 1.02
Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica (2012) 1.01
Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. Blood (2005) 1.00
Haematopoietic stem cell transplantation for Shwachman-Diamond disease: a study from the European Group for blood and marrow transplantation. Br J Haematol (2005) 0.99
Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial. PLoS One (2013) 0.99
Development of an integrative transformation system for the opportunistic pathogenic yeast Candida lusitaniae using URA3 as a selection marker. Yeast (2004) 0.99
The survey on cellular and engineered tissue therapies in Europe in 2009. Tissue Eng Part A (2011) 0.99
The survey on cellular and engineered tissue therapies in Europe in 2010. Tissue Eng Part A (2012) 0.98
Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates: indirect evidence of a fluconazole uptake transporter. Antimicrob Agents Chemother (2003) 0.97
Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol (2013) 0.97
The survey on cellular and engineered tissue therapies in Europe in 2012. Tissue Eng Part A (2015) 0.96
Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood (2011) 0.96
Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation. Transfusion (2009) 0.95
Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation (2010) 0.95
Differentiation between atypical isolates of Candida lusitaniae and Candida pulcherrima by determination of mating type. J Clin Microbiol (2005) 0.94
Neural progenitors derived from human embryonic stem cells are targeted by allogeneic T and natural killer cells. J Cell Mol Med (2009) 0.93
Comparison of a powered bone marrow biopsy device with a manual system: results of a prospective randomised controlled trial. J Clin Pathol (2012) 0.93
Activating CD94:NKG2C and inhibitory CD94:NKG2A receptors are expressed by distinct subsets of committed CD8+ TCR alphabeta lymphocytes. Eur J Immunol (2004) 0.93
Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. PLoS One (2009) 0.91
Role of primacy of birth in HLA-identical sibling transplantation. Blood (2007) 0.91
The survey on cellular and engineered tissue therapies in Europe in 2011. Tissue Eng Part A (2013) 0.91
[Can we do without intravenous polyclonal immunoglobines (IVIg)?]. Rev Med Suisse (2009) 0.91
Is acute fibrinous and organizing pneumonia the expression of immune dysregulation? J Pediatr Hematol Oncol (2013) 0.90
Genital chronic GVHD in men after hematopoietic stem cell transplantation: a single-center cross-sectional analysis of 155 patients. Biol Blood Marrow Transplant (2013) 0.90
Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases. Pediatr Res (2012) 0.89
In vitro activated human T lymphocytes very efficiently attach to allogenic multipotent mesenchymal stromal cells and transmigrate under them. J Cell Physiol (2008) 0.89
Hepatitis-associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party. Br J Haematol (2010) 0.89
TNF-alpha induces the generation of Langerin/(CD207)+ immature Langerhans-type dendritic cells from both CD14-CD1a and CD14+CD1a- precursors derived from CD34+ cord blood cells. Eur J Immunol (2003) 0.89
IL-21 promotes survival and maintains a naive phenotype in human CD4+ T lymphocytes. Int Immunol (2008) 0.88
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol (2009) 0.88
Humoral and cellular rejection after combined liver-kidney transplantation in low immunologic risk recipients. Transpl Int (2008) 0.87
Hematopoietic stem cell transplantation activity in Europe. Curr Opin Hematol (2013) 0.87
Implication of indolamine 2,3 dioxygenase in the tolerance toward fetuses, tumors, and allografts. J Leukoc Biol (2013) 0.87
CD56bright NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells. Eur J Immunol (2010) 0.86
Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components. Transfusion (2012) 0.86
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica (2011) 0.85
Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol (2015) 0.84
Selection of unrelated bone marrow donors by serology, molecular typing and cellular assays. Transpl Immunol (2002) 0.84
Human CD34+ CD11b- cord blood stem cells generate in vitro a CD34- CD11b+ subset that is enriched in langerin+ Langerhans dendritic cell precursors. Exp Hematol (2006) 0.83
Pluripotent stem cells as new drugs? The example of Parkinson's disease. Int J Pharm (2009) 0.83
Lung resection in hematologic patients with pulmonary invasive fungal disease. Chest (2012) 0.83
The transcription factor RFX protects MHC class II genes against epigenetic silencing by DNA methylation. J Immunol (2009) 0.82
Diagnosis and treatment of acquired aplastic anemia. Hematol Oncol Clin North Am (2009) 0.82
Immunosuppression with ALG and CsA is first line treatment in children with SAA lacking an HLA identical sibling. Pediatr Blood Cancer (2005) 0.81
Natural killer cell receptor--repertoire and functions after induction therapy by polyclonal rabbit anti-thymocyte globulin in unsensitized kidney transplant recipients. Clin Immunol (2010) 0.81
Microchimerism after liver transplantation: absence of rejection without abrogation of anti-donor cytotoxic T-lymphocyte-mediated alloreactivity. Liver Transpl (2005) 0.81
Pseudovasculitis and corticosteroid therapy. Clin Rheumatol (2005) 0.81
The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children. PLoS One (2013) 0.80
Monitoring of CD4+CD25highIL-7Rαhigh activated T cells in kidney transplant recipients. Clin J Am Soc Nephrol (2011) 0.80
Anti-HLA antibody repertoire after IVIg infusion in highly sensitized patients waiting for kidney transplantation. Swiss Med Wkly (2006) 0.79